Cullinan Therapeutics Yönetim

Yönetim kriter kontrolleri 1/4

Cullinan Therapeutics CEO'su Nadim Ahmed, Oct2021 tarihinde atandı, in görev süresi 4.5 yıldır. in toplam yıllık tazminatı $ 7.68M olup, şirket hissesi ve opsiyonları dahil olmak üzere 8.8% maaş ve 91.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.25% ine doğrudan sahiptir ve bu hisseler $ 2.06M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.2 yıl ve 2.8 yıldır.

Anahtar bilgiler

Nadim Ahmed

İcra Kurulu Başkanı

US$7.7m

Toplam tazminat

CEO maaş yüzdesi	8.78%
CEO görev süresi	4.5yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	4.2yrs
Yönetim Kurulu ortalama görev süresi	2.8yrs

Son yönetim güncellemeleri

Recent updates

Here's Why We're Watching Cullinan Therapeutics' (NASDAQ:CGEM) Cash Burn Situation

Oct 10

Here's Why We're Watching Cullinan Therapeutics' (NASDAQ:CGEM) Cash Burn Situation

Jun 21

Cullinan Therapeutics: Attractive Pipeline Progress, But We Will Wait For Complete Phase 2b Data

Apr 08

Cullinan Therapeutics (NASDAQ:CGEM) Is In A Good Position To Deliver On Growth Plans

Feb 27

Cullinan Therapeutics: Casting A Wide Net With Their Pipeline

Jan 08

Cullinan Therapeutics (NASDAQ:CGEM) Is In A Good Position To Deliver On Growth Plans

Nov 20

Cullinan Therapeutics: Fundraising Capability, Emergence In Autoimmune Disease

Aug 30

Checking Into Cullinan Therapeutics

Jun 09

Companies Like Cullinan Therapeutics (NASDAQ:CGEM) Are In A Position To Invest In Growth

Apr 23

Cullinan Oncology: Modality-Agnostic Approach To Yield Fruit In Coming Years

Sep 22

Cullinan Oncology: One Of The Leaders In Cancer Treatment Development

Sep 14

Cullinan Oncology grants stock options for 125.7K shares

Sep 02

Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth

Jun 24

Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation

Mar 05

CEO Tazminat Analizi

Nadim Ahmed'un ücretlendirmesi Cullinan Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Dec 31 2025	n/a	n/a	-US$220m
Sep 30 2025	n/a	n/a	-US$217m
Jun 30 2025	n/a	n/a	-US$207m
Mar 31 2025	n/a	n/a	-US$179m
Dec 31 2024	US$8m	US$675k	-US$167m
Sep 30 2024	n/a	n/a	-US$144m
Jun 30 2024	n/a	n/a	-US$142m
Mar 31 2024	n/a	n/a	-US$132m
Dec 31 2023	US$4m	US$649k	-US$153m
Sep 30 2023	n/a	n/a	-US$156m
Jun 30 2023	n/a	n/a	-US$142m
Mar 31 2023	n/a	n/a	US$65m
Dec 31 2022	US$4m	US$618k	US$111m
Sep 30 2022	n/a	n/a	US$105m
Jun 30 2022	n/a	n/a	US$113m
Mar 31 2022	n/a	n/a	-US$78m
Dec 31 2021	US$39m	US$125k	-US$66m

Tazminat ve Piyasa: Nadim 'nin toplam tazminatı ($USD 7.68M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 3.70M ).

Tazminat ve Kazançlar: Nadim şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Nadim Ahmed (57 yo)

4.5yrs

Görev süresi

US$7,684,366

Tazminat

Mr. Nadim Ahmed is Director of Disc Medicine, Inc. from July 2025. Mr. Ahmed has been a President, Chief Executive Officer and Director of Cullinan Therapeutics, Inc. (formerly known as Cullinan Oncology,...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Nadim Ahmed	President	4.5yrs	US$7.68m	0.25% $ 2.1m
Mary Fenton	Chief Financial Officer	2yrs	US$4.14m	0.21% $ 1.7m
Jeffrey Jones	Chief Medical Officer	4.2yrs	US$3.39m	0.11% $ 899.2k
Patrick Baeuerle	Co-Founder	no data	US$1.96m	Veri yok
Jennifer Michaelson	Chief Scientific Officer	2.8yrs	Veri yok	0.28% $ 2.4m
Nicholas Smith	Head of Investor Relations	no data	Veri yok	Veri yok
Jacquelyn Sumer	Chief Legal Officer	3.7yrs	Veri yok	0.089% $ 745.1k
Steve Andre	Chief Human Resources Officer	4.3yrs	Veri yok	Veri yok
Corinne Savill	Chief Business Officer	9.2yrs	Veri yok	0.25% $ 2.1m
Rose Weldon	Senior Vice President of Corporate Affairs	2.3yrs	Veri yok	Veri yok
Kevin Johnston	Chief Technical Operations Officer	4.3yrs	Veri yok	Veri yok

4.2yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim: CGEM 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Nadim Ahmed	President	4.5yrs	US$7.68m	0.25% $ 2.1m
Patrick Baeuerle	Co-Founder	2.8yrs	US$1.96m	Veri yok
Stephen Webster	Independent Director	5.6yrs	US$229.86k	0% $ 0
Anthony Rosenberg	Independent Chairman of the Board	8.7yrs	US$258.41k	0.074% $ 622.8k
Ronald Levy	Member of Scientific Advisory Board	2.8yrs	Veri yok	Veri yok
Mary Thistle	Director	1.7yrs	US$292.55k	Veri yok
Anthony Tolcher	Member of Scientific Advisory Board	2.8yrs	Veri yok	Veri yok
Bahija Jallal	Member of Scientific Advisory Board	2.8yrs	Veri yok	Veri yok
Chaim Putterman	Member of Scientific Advisory Board	2.3yrs	Veri yok	Veri yok
David Meek	Independent Director	1.9yrs	US$304.48k	0% $ 0
Patricia M. LoRusso	Member of Scientific Advisory Board	2.8yrs	Veri yok	Veri yok
David McDermott	Member of Scientific Advisory Board	2.8yrs	Veri yok	Veri yok

2.8yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CGEM 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.8 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/04/23 17:58
Gün Sonu Hisse Fiyatı	2026/04/23 00:00
Kazançlar	2025/12/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Cullinan Therapeutics, Inc. 16 Bu analistlerden 12, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Julian Harrison	BTIG
Samantha Lynn Semenkow	Citigroup Inc
Joshua Schimmer	Evercore ISI

Cullinan Therapeutics Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

President recently sold US$223k worth of stock

President recently sold US$99k worth of stock

Cullinan Therapeutics, Inc. Announces Board Changes, Effective August 7, 2025

Cullinan Therapeutics, Inc., Annual General Meeting, Jun 12, 2025

President recently sold US$107k worth of stock

President recently sold US$100k worth of stock

Recent updates

We're Hopeful That Cullinan Therapeutics (NASDAQ:CGEM) Will Use Its Cash Wisely

Consensus revenue estimates decrease by 39%

President recently sold US$223k worth of stock

Cullinan Therapeutics: Thesis Strengthening For This T-Cell Engager Specialist

Is Cullinan Therapeutics (NASDAQ:CGEM) In A Good Position To Invest In Growth?

President recently sold US$99k worth of stock

Price target increased by 11% to US$28.78

Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation At the 67Th Ash Meeting

Cullinan Therapeutics, Inc. Receives Fda Fast Track Designation for Cln-049, A Novel Flt3xcd3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia

Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Cullinan Therapeutics, Inc. to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting

Cullinan Therapeutics, Inc. Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025

Taiho Oncology and Cullinan Therapeutics Announces to Present Data on Zipalertinib in Patients with Nsclc with Egfr Mutations and Active Brain Metastases At the Esmo Congress 2025

Here's Why We're Watching Cullinan Therapeutics' (NASDAQ:CGEM) Cash Burn Situation

Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib at the IASLC 2025 World Conference on Lung Cancer

Cullinan Therapeutics, Inc. Announces Board Changes, Effective August 7, 2025

Cullinan Therapeutics, Inc.(NasdaqGS:CGEM) dropped from Russell 3000E Growth Index

Here's Why We're Watching Cullinan Therapeutics' (NASDAQ:CGEM) Cash Burn Situation

Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology

Cullinan Therapeutics, Inc., Taiho Pharmaceutical Co., Ltd., and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025

Price target decreased by 12% to US$28.25

Cullinan Therapeutics, Inc. to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjogren's Disease in the United States

Cullinan Therapeutics, Inc., Annual General Meeting, Jun 12, 2025

Cullinan Therapeutics, Inc. to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Cullinan Therapeutics, Inc. Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978

Cullinan Therapeutics: Attractive Pipeline Progress, But We Will Wait For Complete Phase 2b Data

Consensus revenue estimates fall by 52%

President recently sold US$107k worth of stock

Cullinan Therapeutics (NASDAQ:CGEM) Is In A Good Position To Deliver On Growth Plans

Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy

New major risk - Shareholder dilution

Cullinan Therapeutics: Casting A Wide Net With Their Pipeline

President recently sold US$100k worth of stock

Cullinan Therapeutics (NASDAQ:CGEM) Is In A Good Position To Deliver On Growth Plans

Cullinan Therapeutics, Inc. Announces Preclinical Data for CLN-978, a CD19-Directed T Cell Engager, to Be Presented at ACR Convergence 2024

Cullinan Therapeutics, Inc. to Present Preclinical Data for CLN-978, a CD19-Directed T Cell Engager, at ACR Convergence 2024

Cullinan Therapeutics, Inc Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus

Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus

Cullinan Therapeutics, Inc. Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus

Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024

Chief Scientific Officer notifies of intention to sell stock

Cullinan Therapeutics: Fundraising Capability, Emergence In Autoimmune Disease

Independent Director exercised options to buy US$402k worth of stock.

Checking Into Cullinan Therapeutics

Cullinan Therapeutics, Inc. Announces Positive Initial Data from Pivotal Phase 2b Rezil1 Study of Zipalertinib

Independent Director exercised options to buy US$2.4m worth of stock.

Consensus EPS estimates upgraded to US$3.01 loss

Cullinan Therapeutics, Inc., Annual General Meeting, Jun 26, 2024

Cullinan Therapeutics, Inc. Announces Board Changes

Chief Scientific Officer notifies of intention to sell stock

Consensus revenue estimates increase by 19%

Cullinan Therapeutics, Inc Appoints Mary Kay Fenton as Chief Financial Officer

Companies Like Cullinan Therapeutics (NASDAQ:CGEM) Are In A Position To Invest In Growth

Price target increased by 13% to US$28.71

Cullinan Oncology, Inc. announced that it expects to receive $280.000024 million in funding

Cullinan Oncology, Inc. Announces Resignation of Jeff Trigilio as Chief Financial Officer , Effective from March 29, 2024

Chief Business Officer notifies of intention to sell stock

New minor risk - Shareholder dilution

Cullinan Oncology, Inc. Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines

Cullinan Oncology, Inc. to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023

Price target decreased by 11% to US$25.25

New minor risk - Profitability

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Oncology, Inc. Announces the Launch of the REZILIENT3 Trial

Investor sentiment improves as stock rises 17%

High number of new and inexperienced directors

Chief Development Officer notifies of intention to sell stock

Investor sentiment improves as stock rises 16%

Cullinan Oncology, Inc. Announces First Clinical Data from its Phase 1 Study of CLN-619 in Patients with Advanced Solid Tumors

Cullinan Oncology, Inc. Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, Novel T-Cell Engager for Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma